DISRUPT CAD III—Coverage of TCT Connect 2020 | SCAI

Coronary intravascular lithotripsy (IVL) for treating severe coronary calcification appears promising in the DISRUPT CAD III registry. 384 patients with were enrolled at 47 sites in U.S., U.K., France, and Germany. The results showed the primary safety (freedom from 30-day MAC) and primary efficacy (procedural success defined as successful stent delivery with a residual stenosis <50% without in-hospital MACE) endpoints were achieved in 92.2% and 92.4% of patients, respectively. Notably, no coronary perforations occurred in the trial.  Transient IVL-induced ventricular capture was common but resulted in no clinical sequelae.    

All Editors: David A. Cox, MD, MSCAI, Allison G. Dupont, MD, FSCAI, Kirk N. Garratt, MD, MSc, MSCAI, Cindy L. Grines, MD, MSCAI, Andrew J. Klein, MD, FSCAI, and Jordan Safirstein, MD, FSCAI. 

Other Specialist Resources for Coronary Heart Disease

Including recently published studies, coverage of late-breaking science, updates from clinical trials and registries, and complex case presentations.